BioSpace News Archive

Orthopaedic and Spine Center announced Dr. Jeffrey Carlson, Orthopaedic Spine Surgeon, became the first surgeon in Central and Eastern Virginia area to implant the M6-C™ artificial cervical disc.

MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients with non-alcoholic steatohepatitis (NASH) and fibrosis, that was initiated in March 2019

TELA Bio, Inc. reported financial results for the three months ended September 30, 2019.

Medtronic plc (NYSE:MDT) announced that the U.S. Food and Drug Administration (FDA) recently cleared the Stealth Autoguide™ system, the first cranial robotic platform that integrates with Medtronic’s enabling technology portfolio to create an end-to-end procedural solution

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will provide a corporate update and also participate in a Lunch Plenary Panel titled: “Reshaping the life sciences and healthcare landscape: The impact of pricing, policy and payers”

Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa

The National Council of State Boards of Nursing Board of Directors (NCSBN BOD) voted on Dec. 9, 2019, to raise the passing standard for the NCLEX-PN Examination (the National Council Licensure Examination for Practical Nurses).

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority’s (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that its Board of Directors has appointed Karen N. Prange as a member of the Board.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointments of C. Frank Bennett, Ph.D., as chief scientific officer, and Eric E. Swayze, Ph.D., as senior vice president of research, effective January 1, 2020.